Healthcare
Live Price
Offline$75.43
+1.17% today
1Y Change
+10.50%
Window
Jun 23, 2025 → Jun 10, 2026
Coverage: 243 bars · Jun 23, 2025 → Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Solventum Corporation (SOLV) is a Healthcare stock with a market cap of $11.56B and listed on NYSE. The stock last traded around $75.43 and up 10.5% across the available one-year price window (Jun 23, 2025 → Jun 10, 2026). Baseline metrics include revenue growth of +0.9%, EPS growth of +222.7%, a dividend yield of 0.0%. What stands out right now is revenue +0.9%, EPS +222.7%, free cash flow -101.2% with operating margin 26.2% and ROIC 17.8%. Valuation is more restrained than many high-expectation growth names at P/E 7.5 and price/sales 1.4. Stock Foundry combines SOLV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SOLV
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SOLV Max Drawdown
-27.46%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SOLV and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$8.2B
+0.5% YoY
FY Net Income
$1.5B
+8.7% YoY
Free Cash Flow
$1.9B
+34.8% YoY
Revenue Growth
+0.9%
EPS Growth
+222.7%
Gross Margin
53.5%
Net Margin
18.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 8.3B | 8.3B | 8.2B | 8.1B | 8.2B |
| Gross Profit | 4.5B | 4.6B | 4.7B | 4.7B | 4.9B |
| Operating Income | 2.2B | 1.0B | 1.7B | 1.7B | 1.9B |
| EBITDA | 2.5B | 1.5B | 2.2B | 2.3B | 2.5B |
| Net Income | 1.6B | 479M | 1.3B | 1.3B | 1.5B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 878M | 762M | 194M | 61M | 91M |
| Total Assets | 14.3B | 14.5B | 13.9B | 13.6B | 14.1B |
| Total Liabilities | 9.2B | 11.5B | 2.3B | 1.9B | 2.0B |
| Shareholder Equity | 5.0B | 3.0B | 11.7B | 11.7B | 12.1B |
| Total Debt | 5.0B | 8.0B | 8.3B | 0 | 0 |
| Net Debt | 4.2B | 7.2B | 8.1B | -61M | -91M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2.2B
+31.1% YoY
Capital Expenditures
277M
-10.4% YoY
Free Cash Flow
1.9B
+34.8% YoY
Key ratios
Gross Margin
53.5%
Operating Margin
26.2%
Net Margin
18.7%
ROE
36.7%
Debt / Equity
1.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.